Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.

J Am Heart AssocSep 9, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Ensieh S Mansouri, Flavia Queiroga, Lucas Mendes Barbosa et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the impact of tirzepatide on atrial fibrillation incidence in adults with overweight or obesity, analyzing data from 10 randomized controlled trials involving 6515 participants. The results indicated a pooled odds ratio of 2.20 for atrial fibrillation, but the findings suggest no significant association with atrial fibrillation or atrial arrhythmia.

Key findings

  • Pooled odds ratio for atrial fibrillation was 2.20 (95% CrI, 0.81-6.75).
  • Pooled odds ratio for atrial arrhythmia was 2.16 (95% CrI, 0.90-5.87).
  • Pooled odds ratio for any arrhythmia was 1.84 (95% CrI, 1.04-3.90).
  • Event rates for arrhythmias were low, warranting cautious interpretation.

Why it matters

Understanding the cardiovascular safety profile of tirzepatide is crucial for clinicians managing patients with obesity, as it informs risk assessment and treatment decisions regarding potential arrhythmias.

Source

PubMed · PMID 42714458

Published in J Am Heart Assoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.